Immuron Travelan® continued strong sales growth
17 janv. 2025 06h00 HE
|
Immuron Limited
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9...
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
15 janv. 2025 06h00 HE
|
Immuron Limited
Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal...
Immuron Announces Travelan® Clinical Trial Update
14 janv. 2025 06h00 HE
|
Immuron Limited
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology ResultsTravelan® (IMM-124E) Phase 2...
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
02 déc. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small...
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
21 nov. 2024 18h33 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
16 oct. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a...
Immuron Travelan® continued strong sales growth
15 oct. 2024 06h00 HE
|
Immuron Limited
Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter...
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
04 oct. 2024 06h30 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
05 sept. 2024 11h54 HE
|
Immuron Limited
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on...
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
16 août 2024 06h00 HE
|
Immuron Limited
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16,...